Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.
Okkerse P, Hay JL, Versage E, Tang Y, Galluppi G, Ravina B, Verma A, Williams L, Aycardi E, Groeneveld GJ. Okkerse P, et al. Among authors: aycardi e. Br J Clin Pharmacol. 2016 Jul;82(1):108-17. doi: 10.1111/bcp.12941. Epub 2016 May 13. Br J Clin Pharmacol. 2016. PMID: 27016000 Free PMC article. Clinical Trial.
First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica.
Rolan PE, O'Neill G, Versage E, Rana J, Tang Y, Galluppi G, Aycardi E. Rolan PE, et al. Among authors: aycardi e. PLoS One. 2015 May 11;10(5):e0125034. doi: 10.1371/journal.pone.0125034. eCollection 2015. PLoS One. 2015. PMID: 25962165 Free PMC article. Clinical Trial.
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects.
Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, Yoon E, Gandhi MD, Spiegelstein O, Aycardi E. Cohen-Barak O, et al. Among authors: aycardi e. Cephalalgia. 2018 Nov;38(13):1960-1971. doi: 10.1177/0333102418771376. Epub 2018 Apr 18. Cephalalgia. 2018. PMID: 29667896 Clinical Trial.
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME. Silberstein SD, et al. Among authors: aycardi e. Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18. Headache. 2019. PMID: 30450545 Clinical Trial.
A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.
Gutman D, Hellriegel E, Aycardi E, Bigal ME, Kunta J, Chitra R, Kansagra S, Kidron OS, Knebel H, Linder S, Ma Y, Pierce M, Winner PK, Spiegelstein O. Gutman D, et al. Among authors: aycardi e. Headache. 2016 Sep;56(8):1300-9. doi: 10.1111/head.12895. Epub 2016 Jul 29. Headache. 2016. PMID: 27474357 Clinical Trial.
Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Silberstein SD, et al. Among authors: aycardi e. N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038. N Engl J Med. 2017. PMID: 29171818 Free article. Clinical Trial.
30 results